Author:
Ye Chaohui,Lyu Qin,Jiang Linyan,Yu Li,Xu Yinquan,Zhang Jie,Lu Xiaodong
Funder
Natural Science Foundation of Ningbo
Zhejiang Province Public Welfare Technology Application Research Project
Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference27 articles.
1. Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1):e138–44.
2. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020;2:CD003481.
3. Sivanandan S, Bali V, Soraisham AS, Harabor A, Kamaluddeen M. Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. Am J Perinatol. 2013;30(9):745–50.
4. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007;150(3):229–34.
5. Olgun H, Ceviz N, Kartal I, Caner I, Karacan M, Tastekin A, et al. Repeated courses of oral ibuprofen in premature infants with patent ductus arteriosus: efficacy and safety. Pediatr Neonatol. 2017;58(1):29–35.